250 related articles for article (PubMed ID: 28837524)
1. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors.
Fay S; Ungar B; Paul S; Levartovsky A; Yavzori M; Fudim E; Picard O; Eliakim R; Ben-Horin S; Roblin X; Kopylov U
Inflamm Bowel Dis; 2017 Nov; 23(11):1924-1929. PubMed ID: 28837524
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis.
Cañete F; Mañosa M; Pérez-Martínez I; Barreiro-de Acosta M; González-Sueyro RC; Nos P; Iglesias-Flores E; Gutiérrez A; Bujanda L; Gordillo J; Ríos León R; Casanova MJ; Villoria A; Rodríguez-Lago I; López Serrano P; García-Herola A; Ramírez-de la Piscina P; Navarro-Llavat M; Taxonera C; Barrio J; Ramos L; Navarro P; Benítez-Leiva O; Calafat M; Domènech E;
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00218. PubMed ID: 32955190
[TBL] [Abstract][Full Text] [Related]
3. Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
Collins M; Sarter H; Gower-Rousseau C; Koriche D; Libier L; Nachury M; Cortot A; Zerbib P; Blanc P; Desreumaux P; Colombel JF; Peyrin-Biroulet L; Pineton de Chambrun G
J Crohns Colitis; 2017 Mar; 11(3):281-288. PubMed ID: 27578800
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
Cañete F; Mañosa M; Casanova MJ; González-Sueyro RC; Barrio J; Bermejo F; Nos P; Iglesias-Flores E; García-Planella E; Pérez-Calle JL; Vicente R; Vera M; Ramos L; Rivero M; De Francisco R; Montserrat A; Benítez O; Navarro P; Taxonera C; Hinojosa E; Márquez-Mosquera L; Navarro-Llavat M; Ramírez-de la Piscina P; Gomollón F; Rodríguez-Alonso L; Núñez-Alonso A; Fernández-Salazar L; Almela P; Ríos León R; De Castro L; Gisbert JP; Ricart E; Cabré E; Domènech E;
Inflamm Bowel Dis; 2019 Oct; 25(11):1862-1870. PubMed ID: 31006801
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
6. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.
Aguas M; Bastida G; Cerrillo E; Beltrán B; Iborra M; Sánchez-Montes C; Muñoz F; Barrio J; Riestra S; Nos P
World J Gastroenterol; 2012 Aug; 18(32):4391-8. PubMed ID: 22969204
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
[TBL] [Abstract][Full Text] [Related]
9. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
10. Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
Sorrentino D; Marino M; Dassopoulos T; Zarifi D; Del Bianco T
PLoS One; 2015; 10(12):e0144900. PubMed ID: 26670274
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study.
Tursi A; Elisei W; Picchio M; Zampaletta C; Pelecca G; Faggiani R; Brandimarte G
Tech Coloproctol; 2014 Nov; 18(11):1041-6. PubMed ID: 24915941
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Selvaraj F; Princen F; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Gearry RB; Selby W; Bell SJ; Brown SJ; Connell WR
J Crohns Colitis; 2018 May; 12(6):653-661. PubMed ID: 29385469
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
Clark-Snustad KD; Singla A; Lee SD
Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
15. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
De Gregorio M; Lee T; Krishnaprasad K; Amos G; An YK; Bastian-Jordan M; Begun J; Borok N; Brown DJM; Cheung W; Connor SJ; Gerstenmaier J; Gilbert LE; Gilmore R; Gu B; Kutaiba N; Lee A; Mahy G; Srinivasan A; Thin L; Thompson AJ; Welman CJ; Yong EXZ; De Cruz P; van Langenberg D; Sparrow MP; Ding NS
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1306-1314. PubMed ID: 34389484
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis.
De Cruz P; Kamm MA; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits S; Florin TH; Gibson PR; Debinski H; Gearry RB; Macrae FA; Leong RW; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
Aliment Pharmacol Ther; 2015 Oct; 42(7):867-79. PubMed ID: 26314275
[TBL] [Abstract][Full Text] [Related]
17. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
Rodríguez-Lago I; Hoyo JD; Pérez-Girbés A; Garrido-Marín A; Casanova MJ; Chaparro M; Fernández-Clotet A; Castro-Poceiro J; García MJ; Sánchez S; Ferreiro-Iglesias R; Bastón I; Piqueras M; Careda LEIB; Mena R; Suárez C; Cordón JP; López-García A; Márquez L; Arroyo M; Alfambra E; Sierra M; Cano N; Delgado-Guillena P; Morales-Alvarado V; Aparicio JC; Guerra I; Aulló C; Merino O; Arranz L; Hidalgo MA; Llaó J; Plaza R; Molina G; Torres P; Pérez-Galindo P; Romero MG; Herrera-deGuise C; Armesto E; Mesonero F; Frago-Larramona S; Benítez JM; Calvo M; Martín MDCL; Elorza A; Larena A; Peña E; Rodríguez-Grau MDC; Miguel-Criado J; Botella B; Olmos JA; López L; Aguirre U; Gisbert JP;
United European Gastroenterol J; 2020 Nov; 8(9):1056-1066. PubMed ID: 32723069
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease.
Chaparro M; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Hernández-Breijo B; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Bermejo F; Beltrán B; Rodríguez Pescador A; Banales JM; Olivares D; Aguilar-Melero P; Menchén L; Ferreiro-Iglesias R; Blazquez Gomez I; Benítez García B; Guijarro LG; Marin A; Bernardo D; Gisbert JP;
Eur J Gastroenterol Hepatol; 2020 May; 32(5):588-596. PubMed ID: 32251204
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine.
Zarubova K; Hradsky O; Copova I; Rouskova B; Pos L; Skaba R; Bronsky J
J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):207-211. PubMed ID: 28248209
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
